The Manufacturers Life Insurance Company Acquires New Shares in Omnicell, Inc. $OMCL

The Manufacturers Life Insurance Company acquired a new position in shares of Omnicell, Inc. (NASDAQ:OMCL) during the 2nd quarter, Holdings Channel.com reports. The firm acquired 22,350 shares of the company’s stock, valued at approximately $928,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Raymond James Financial Inc. bought a new stake in shares of Omnicell in the second quarter worth about $26,000. Versant Capital Management Inc lifted its holdings in shares of Omnicell by 38.7% during the 2nd quarter. Versant Capital Management Inc now owns 1,053 shares of the company’s stock valued at $44,000 after purchasing an additional 294 shares in the last quarter. Clearstead Advisors LLC grew its position in shares of Omnicell by 12,180.0% in the 4th quarter. Clearstead Advisors LLC now owns 1,228 shares of the company’s stock valued at $56,000 after purchasing an additional 1,218 shares during the period. Kemnay Advisory Services Inc. bought a new stake in Omnicell during the 4th quarter worth approximately $58,000. Finally, Parkside Financial Bank & Trust increased its stake in Omnicell by 1,708.1% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,338 shares of the company’s stock worth $61,000 after purchasing an additional 1,264 shares in the last quarter. 97.70% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

OMCL has been the topic of several research analyst reports. KeyCorp restated an “overweight” rating on shares of Omnicell in a report on Monday, August 24th. Wall Street Zen raised shares of Omnicell from a “buy” rating to a “strong-buy” rating in a research report on Sunday, May 10th. Zacks Research lowered shares of Omnicell from a “hold” rating to a “strong sell” rating in a report on Friday, August 7th. Weiss Ratings raised shares of Omnicell from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 18th. Finally, Wells Fargo & Company reduced their target price on shares of Omnicell from $55.00 to $50.00 and set an “overweight” rating for the company in a research note on Friday, July 31st. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Omnicell presently has an average rating of “Moderate Buy” and an average target price of $57.86.

Omnicell Stock Down 1.3%

Shares of Omnicell stock opened at $34.37 on Friday. The firm has a market cap of $1.56 billion, a PE ratio of 40.92, a P/E/G ratio of 0.86 and a beta of 0.97. The business’s 50 day simple moving average is $39.34 and its 200 day simple moving average is $39.24. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.43 and a current ratio of 1.64. Omnicell, Inc. has a 52-week low of $29.06 and a 52-week high of $55.00.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings results on Thursday, July 30th. The company reported $0.94 earnings per share for the quarter, topping analysts’ consensus estimates of $0.47 by $0.47. The firm had revenue of $312.21 million during the quarter, compared to the consensus estimate of $310.21 million. Omnicell had a return on equity of 5.66% and a net margin of 3.13%.The business’s revenue was up 7.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.45 EPS. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. On average, analysts predict that Omnicell, Inc. will post 1.41 earnings per share for the current fiscal year.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.